This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Blanco-Favela, F Articles by Leaños-Miranda, A Search for Related Content PubMed PubMed Citation Articles by Blanco-Favela, F Articles by Leaños-Miranda, A Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Medline Plus Health Information Lupus Social Bookmarking                         What's this?

Analysis of anti-prolactin autoantibodies in systemic lupus erythematosus

Immunology Research Unit, Paediatric Hospital, National Medical Center ‘Siglo XXI’, Instituto Mexicano del Seguro Social, México City, México; Immunology Research Unit, Paediatric Hospital, National Medical Centre Siglo XXI, IMSS, Av. Cuauhtémoc 330, Col. Doctores, PO Box 73032, C.P. 06725 México, D.F., Méxicofblanco{at}terra.com.mx

K Chavez-Rueda

A Leaños-Miranda

Immunology Research Unit, Paediatric Hospital, National Medical Center ‘Siglo XXI’, Instituto Mexicano del Seguro Social, México City, México

Evidence has shown that prolactin is an essential component of an effective immune response. In systemic lupus erythematosus, clinical trials have produced controversial information about the role of PRL. Some results find association between serum PRL levels and disease activity. In contrast, other authors did not find this. Recently, autoantibodies against prolactin in SLE patients have been described. One hundred percent of SLE patients with anti-PRL autoantibodies had hyperprolactinemia (hPRL) and 31.7% of the SLE patients classified with idiopathic hPRL had anti-prolactin antibodies. A similar result was found in 103 pediatric SLE patients. The patients with idiopathic hyperprolactinemia and anti-PRL autoantibodies had less clinical and serological lupus activity than the SLE patients with idiopathic hyperprolactinemia, but without anti-PRL autoantibodies.

This evidence suggests that anti-PRL autoantibodies or the complex with any other molecule, like macroprolactinemia (big-big PRL) could have attenuated biological activity and this could explain why some clinical studies did not find any association between serum PRL levels and disease activity in SLE patients. However, studies in vitro have shown normal or elevated biological activity in Nb2 cell lines using PRL from serum with anti-PRL autoantibodies from patients with or without autoimmune diseases.

Several conclusions could be drawn. One is that while a set of hyperprolactinemic SLE patients display autoantibodies against PRL, it is not clear what role these autoantibodies play in the whole system. However, until now, we knew that the patients with antibodies to PRL lacked the clinical symptoms of hyperprolactinemia such as menstrual disturbances and/or galactorrhea and show less clinical and serological lupus activity.

Key Words: autoimmunity • prolactin • anti-prolactin antibodies • hyperprolactinemia

Lupus, Vol. 10, No. 10, 757-761 (2001)
DOI: 10.1191/096120301717165001


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. Hattori, Y. Nakayama, K. Kitagawa, T. Li, and C. Inagaki Development of Anti-PRL (Prolactin) Autoantibodies by Homologous PRL in Rats: A Model for Macroprolactinemia Endocrinology, May 1, 2007; 148(5): 2465 - 2470. [Abstract] [Full Text] [PDF]

				N. Hattori, K. Ikekubo, Y. Nakaya, K. Kitagawa, and C. Inagaki Immunoglobulin G Subclasses and Prolactin (PRL) Isoforms in Macroprolactinemia Due to Anti-PRL Autoantibodies J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3036 - 3044. [Abstract] [Full Text] [PDF]

				M Garcia, M E Colombani-Vidal, C C Zylbersztein, A Testi, J Marcos, A Arturi, J Babini, and H E Scaglia Analysis of molecular heterogeneity of prolactin in human systemic lupus erythematosus Lupus, August 1, 2004; 13(8): 575 - 583. [Abstract] [PDF]

				I Mendez, J Alcocer-Varela, A Parra, A Lava-Zavala, D A de la Cruz, D Alarcon-Segovia, and F Larrea Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin Lupus, January 1, 2004; 13(1): 45 - 53. [Abstract] [PDF]

				L.-y. Yu-Lee Stimulation of interferon regulatory factor-1 by prolactin Lupus, October 1, 2001; 10(10): 691 - 699. [Abstract] [PDF]